Jean-Yves Blay, MD is a medical oncologist, researcher, and professor. He currently holds the position of General Director of the Centre Léon Bérard, in Lyon, France, and additionally maintains active roles at this institution including Professor of Medical Oncology at the Université Claude Bernard Lyon 1, Head of the Integrated Research Site of Lyon (LYric) of the French National Cancer Institute, Director of the Network of Reference Centers for Sarcomas in France, Chairman of the French Sarcoma Group, and Director of the Institute for Clinical Science.
Dr. Blay’s research focuses on sarcomas, targeted treatment of cancer, the biology of breast carcinoma and the relationship between tumor immunologic microenvironment and malignant cells with the goal of clinical applications. He is a member of the European Union Committee of Experts of Rare Diseases (EUCERD) and the European Commission’s Scientific Panel for Health (SPH) and is Faculty Coordinator of the European Society of Medical Oncology (ESMO). Dr. Blay has also served as President of the European Organization for Research and Treatment of Cancer (EORTC) from 2009-2012.
John Condeelis, Ph.D. is The Judith and Burton P. Resnick Chair in Translational Research, Professor and Co-Chairman of the Department of Anatomy and Structural Biology at the Albert Einstein College of Medicine (AECOM).
He is the director of the Cancer Center program “Tumor microenvironment and Metastasis”, co-Director of the Gruss Lipper Biophotonics Center, dedicated to the development and application of optical imaging technologies, and co-director of the Integrated Imaging Program, dedicated to the validation of high resolution probes in clinical imaging. His training is in nuclear physics, optical physics and cell/cancer biology. His current research interest is in tumor cell motility, chemotaxis and invasion during tumor metastasis. He has pioneered the use of combined multiphoton imaging with expression analysis to derive gene expression signatures that define the pathways used by tumor cells to move and invade blood vessels. He discovered the Invasion Signature of breast tumors. He has held elected office in national societies, served on numerous study sections at NIH and the ACS and as Chairman of the Physiology and Cell Biology Study Section, Chairman of the Gordon Conference on Motile Systems, and the Board of Scientific Councilors at the NIH. He has served on editorial boards of prominent journals and is currently associate editor of “Intravital.”
John de Groot, M.D. is a translational and clinical neuro-oncologist in the Department of Neuro-Oncology at the University of Texas – MD Anderson Cancer Center in Houston, Texas whose research focuses on the field of glioma angiogenesis and molecularly targeted therapy.
Dr. de Groot is the PI of multiple clinical trials involving novel agents being tested in patients with glioblastoma. His research focuses on mechanisms of resistance, biomarker development, and the identification of novel therapeutic approaches to overcome resistance to antiangiogenic therapy. Other areas of research involve prospective molecular profiling of patient tumors and the identification of subgroups of glioma with sensitivity to specific molecularly targeted agents. A broad background in both clinical and laboratory-based research provides a unique perspective on targeted therapy and the integration of novel treatments into the clinic for the treatment of patients with brain tumors.
Michele De Palma, Ph.D. is an assistant professor at the Swiss Institute for Experimental Cancer Research (ISREC), Swiss Federal Institute of Technology Lausanne (EPFL). His current research interests focus is on how macrophages modulate tumor responses to anticancer therapies.
Michele has received several awards from the American and European Societies of Gene and Cell Therapy and the European Research Council, and he is an editorial board member of several international journals and is routinely invited to major conferences on inflammation, angiogenesis and cancer. Michele received his Ph.D. from the University of Turin Medical School, where he studied the contribution of monocytes to tumor angiogenesis. He performed post-doctoral training at the San Raffaele Institute (HSR) in Milan to develop new strategies to target biotherapeutics to tumors using engineered monocytes.
Jonathan Fletcher, M.D. is a lab-based medical and pediatric oncologist at Harvard Medical School, Brigham and Women’s Hospital, and Dana-Farber Cancer Institute in Boston, Massachusetts. His research goals have been to identify and characterize oncogenic mutations in sarcoma.
By identifying and studying such mutations, his lab has pinpointed biologic mechanisms regulating sarcoma and GIST cell growth and survival. Dr. Fletcher’s other lab commitments include creation of biologically representative sarcoma cell lines, discovery and validation of novel targeted therapies, and correlative science studies to demonstrate mechanisms of response and resistance to targeted therapies. Dr. Fletcher also coordinates an international research consortium devoted to maximizing therapeutic response in GIST.
F. Stephen Hodi, M.D. is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s Cancer Center and Assistant Professor of Medicine at Harvard Medical School. His research focuses on gene therapy, the development of immune therapies, and first into human studies for malignant melanoma.
Dr. Hodi is a member of the National Comprehensive Cancer Network, the American Society of Clinical Oncology, the Eastern Cooperative Oncology Group Melanoma Committee, the Society for Immunotherapy of Cancer, the American Association for Cancer Research and a founding member of the Society for Melanoma Research. Dr. Hodi received his MD degree from Cornell University Medical College. He competed his postdoctoral training in Internal Medicine at the Hospital of the University of Pennsylvania, and Medical Oncology training at Dana-Farber Cancer Institute.
Filip Janku, M.D., Ph.D. is an Associate Professor in the Department of Investigational Cancer Therapeutics (Phase I Program) at MD Anderson Cancer Center. His research focuses on proof-of-concept clinical trials that possess a pivotal correlative component especially those involving liquid biopsies, molecular profiling of cell-free DNA, and therapies targeting the PI3K, MAPK, IDH and KIT/PDGFR pathways and intratumor therapies.
Dr. Janku received multiple awards for his research efforts, including Sidney Kimmel Scholar award, Khalifa Scholar Award, and several ASCO Merit Awards, as well as an American Association for Cancer Research Scholar-in-Training Award. He obtained his MD and PhD at the Charles University Prague.